Skip to main content
Übersichtsarbeit

Autismus und Stoffwechselerkrankungen - was ist gesichert?

Published Online:https://doi.org/10.1024/1422-4917.33.4.259

Zusammenfassung: Die Ursachen für Autismus sind heterogen und ganz überwiegend genetischer Natur. Eine exakte benennbare Ätiologie wird in weniger als 10% der Fälle gefunden. Die Enttäuschung über den geringen Erfolg bei der Ursachenfindung und zahlreiche Berichte über die Assoziation von Autismus mit Stoffwechselerkrankungen sowie über «Wunderheilungen» bei unterschiedlichsten medikamentösen oder diätetischen Therapien haben bei vielen Ärzten und Eltern zu einer zunehmenden Unsicherheit über die sinnvolle Diagnostik und Behandlung geführt. Diese Arbeit gibt einen Überblick über seltene angeborene Stoffwechselerkrankungen («inborn errors of metabolism»), die nachweislich (z.B. Phenylketonurie, Smith-Lemli-Opitz Syndrom) oder wahrscheinlich (z.B. Succinat-Semialdehyd-Dehydrogenase-Mangel) mit Autismus-spezifischen Symptomen vergesellschaftet sind. In aller Regel weisen betroffene Patienten zusätzliche neurologische Symptome auf. Es werden die zur Diagnostik dieser angeborenen Stoffwechselerkrankungen notwendigen Untersuchungen und mögliche therapeutische Maßnahmen dargestellt. Neben diesen gut definierten Stoffwechselerkrankungen mit der Möglichkeit einer rationalen Therapie wird auch auf Hypothesen über die Entstehung von Autismus durch «Stoffwechselveränderungen» eingegangen, die entweder nicht bewiesen oder nachweislich falsch sind.


Autism and metabolic disorders - a rational approach

Summary: The causes of autism are heterogeneous and predominantly genetically determined. An exact aetiology is found in less than 10% of affected patients. The disappointment about low rates of success in identifying a definite pathology, numerous reports about the association of autism and «metabolic derangements», and rumours of «miraculous cures» after application of various drugs and dietary regimes have resulted in substantial confusion about meaningful diagnostic procedures and rational therapies for subjects with autism. The aim of this report is to give an overview about rare, genetically determined neurometabolic disorders (inborn errors of metabolism) that are evidently (e.g. Smith-Lemli-Opitz Syndrome) or allegedly (e.g. succinate semialdehyde dehydrogenase deficiency) associated with autism-specific symptoms. Affected patients usually display additional neurological symptoms. Procedures required to establish the diagnosis and eventual therapeutic consequences derived from a specific metabolic defect are presented. In addition to these well-defined neurometabolic disorders for which there are rational therapeutic strategies, hypotheses about the association of autism with «metabolic derangements» that could not be confirmed or were clearly falsified are discussed.

Literatur

  • American Academy of Pediatrics, Committee on children with disabilities (2001). Technical report: the pediatrician’s role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics, 107, 1221– 1226 First citation in articleCrossref MedlineGoogle Scholar

  • Baieli, S. , Pavone, L. , Meli, C. , Fiumara, A. , Coleman, M. (2003). Autism and phenlykentonuria. Journal of Autism and Developmental Disorders, 33, 201– 204 First citation in articleCrossref MedlineGoogle Scholar

  • Baird, G. , Cass, H. , Slonims, V. (2003). Diagnosis of autism.. British Medical Journal, 327, 488– 493 First citation in articleCrossref MedlineGoogle Scholar

  • Baynes, K. , Farias, S. T. , Giospe, S. M. (2003). Pyridoxine-dependent seizures and cognition in adulthood.. Developmental Medicine and Child Neurology, 45, 782– 785 First citation in articleCrossref MedlineGoogle Scholar

  • Becker, M. A. , Puig, J. G. , Mateos, F. A. , Jiminez, M. L. , Kim, M. , Simmonds, H. A. (1988). Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness.. American Journal of Medicine, 85, 383– 390 First citation in articleCrossref MedlineGoogle Scholar

  • Berger, R. , Stoker-De Vries, S. A. , Wadman, S. K. , Duran, M. , Beemer, F. A. , de Bree, P. K. , Weits-Binnerts, J. J. , Penders, T. J. , van der Woude, J. K. (1984). Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. Clinica Chimica Acta, 141,, 227– 234 First citation in articleCrossref MedlineGoogle Scholar

  • Bolman, W. M. , Richmond, J. A. (1999). A double-blind, placebo-controlled, cross-over pilot trial of low dose dimethyglycine in patients with autistic disorder. Journal of Autism and Developmental Disorders, 29, 191– 194 First citation in articleCrossref MedlineGoogle Scholar

  • Burd, L. , Stenehejm, A. , Fraceshini, L. A. , Kerbeshian, J. (2000). A 15 year follow up of a boy with pyridoxine-dependent seizures with autism, breath holding and severe mental retardation. Journal of Child Neurology, 15, 763– 765 First citation in articleCrossref MedlineGoogle Scholar

  • Chakrabati, S. , Fombonne, E. (2001). Pervasive developmental disorders in preschool children. Journal of the American Medical Association, 285, 3141– 3142 First citation in articleCrossrefGoogle Scholar

  • Chez, M. , Buchanan, C. , Bagan, B. , Hammer, M. S. , McCarthy, K. S. , Ovrutskaya, I. , Nowinski, C. V. , Cohen, Z. S. (2000). Secretin and autism: a two-part clinical investigation. Journal of Autism and Developmental Disorders, 30, 87– 95 First citation in articleCrossref MedlineGoogle Scholar

  • Coleman, M. , Landgrebe, M. , Landgrebe, A. (1974). Progressive seizures with hyperuricusuria reversed by allopurinol. Archives of Neurology, 31, 238– 242 First citation in articleCrossref MedlineGoogle Scholar

  • Coleman, N. (1989). Autism: nondrug biological treatments. In: C. Gillberg (Ed.), Diagnosis and treatment of autism 219– 235 New York: Plenum Press First citation in articleCrossrefGoogle Scholar

  • DelGuidice-Asch, G. , Simon, L. , Schmeidler, J. , Cunningham-Rundles, C. , Hollander, E. (1999). Brief report: a pilot open clinical trial of intravenous immunglobulin in childhood autism. Journal of Autism and Developmental Disorders, 29, 157– 160 First citation in articleCrossref MedlineGoogle Scholar

  • Dennis, M. , Lockeyer, L. , Lazenby, A. L. , Donelly, R. E. , Wilkinson, M. , Schoonheyt, W. (1999). Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury. Journal of Autism and Developmental Disorders, 29, 5– 17 First citation in articleCrossref MedlineGoogle Scholar

  • D’Eufemia, P. , Celli, M. , Finocchiaro, R. (1996). Abnormal intestinal permeability in children with autism. Acta Pediatrica, 85, 1076– 1079 First citation in articleCrossref MedlineGoogle Scholar

  • Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie, (2003). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Zweite überarbeitete Auflage. Köln: Deutscher Ärzte Verlag. First citation in articleGoogle Scholar

  • Dolske, M. C. , Spollen, J. , McKay, S. , Lancashire, E. , Tolbert, L. A. (1993). A preliminary trial of ascorbic acid as supplemental therapy for autism.. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 17, 765– 774 First citation in articleCrossref MedlineGoogle Scholar

  • Dunn-Geier, J. , Ho, H. H. , Auersperg, E. , Doyle, D. , Eaves, L. , Matsuba, C. , Orbine, E. , Pham, B. , Whiting, S. (2000). Effect of secretin on children with autism. A randomised controlled trial. Developmental Medicine and Child Neurology, 42, 796– 802 First citation in articleCrossref MedlineGoogle Scholar

  • Findling, R. L. , Maxwell, K. , Scotese-Wojtila, C. , Hunag, J. , Yamashita, T. , Wiznitzer, M. (1995). High dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study. Journal of Autism and Developmental Disorders, 25, 61– 70 First citation in articleCrossref MedlineGoogle Scholar

  • Fombonne, E. (1999). The epidemiology of autism: a review. . Psychological Medicine, 29, 769– 786 First citation in articleCrossref MedlineGoogle Scholar

  • Gibson, K. M. , Christensen, E. , Jakobs, C. , Fowler, B. , Clarke, M. A. , Hammersen, G. , Raab, K. , Kobori, J. , Moosa, A. , Vollmer, B. , Rossier, E. , Iafolla, A. K. , Matern, D. , Brouwer, O. F. , Finkelstein, J. , Aksu, F. , Weber, H. D. , Bakkeren, J. A. , Gabreels, F. J. , Bluestone, D. , Barron, T. F. , Beauvais, P. , Rab, D. , Santos, C. , Lehnert, W. (1997). The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxy-butyric aciduria): case reports of 23 new patients. Pediatrics, 99, 567– 574 First citation in articleCrossref MedlineGoogle Scholar

  • Gibson, K. M. , Hoffman, G. F. , Hodson, A. K. , Bottiglieri, T. , Jakobs, C. (1998). 4-hydroxy-butyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics, 29, 14– 22 First citation in articleCrossref MedlineGoogle Scholar

  • Gibson, K. M. , Gupta, M. , Pearl, P. L. , Tuchman, M. , Vezina, L. G. , Snead, O. C. , Smit, L. M. , Jakobs, C. (2003). Significant behavioural disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria. Biological Psychiatry, 54, 763– 768 First citation in articleCrossref MedlineGoogle Scholar

  • Gillberg, C. (1998). Autism and autistic-like conditions. In: J. Aicardi (Ed.), Diseases of the nervous system in children 2nd edition 827– 842 London: MacKeith First citation in articleGoogle Scholar

  • Gillberg, C. , Coleman, M. (1992). The biology of the autistic syndromes. Clinics of Developmental Medicine Nr. 126., London: MacKeith. First citation in articleGoogle Scholar

  • Gropman, A. (2003). Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Annals of Neurology, 54 Supplement, 66– 72 First citation in articleCrossrefGoogle Scholar

  • Gupta, S. , Aggarwal, S. , Heads, C. (1996). Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulins on autistic characteristics.. Journal of Autism and Developmental Disorders, 26, 439– 452 First citation in articleCrossref MedlineGoogle Scholar

  • Hackney, I. M. , Hanley, W. B. , Davidson, W. , Lindsao, L. (1968). Phenylketonuria: mental development, behavior, and termination of low phenylalanine diet. Journal of Pediatrics, 72, 646– 655 First citation in articleCrossref MedlineGoogle Scholar

  • Hoffman, G. F. , Haas, D. (2000). Disorders of cholesterol synthesis. In: J. Fernandes, J.-M. Saudubray & G. van den Berghe (Eds.), Inborn metabolic diseases (third edition 337– 342 erlin Heidelberg New York: Springer-Verlag First citation in articleGoogle Scholar

  • Horvath, K. , Stefanatos, G. , Sokolski, K. N. , Wachtel, R. , Nabors, R. L. , Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorders. Journal of the Association for Academic Minority Physicians, 9, 9– 15 First citation in articleMedlineGoogle Scholar

  • Horvath, K. , Papadimitriou, J. C. , Rabsztyn, A. , Drachenberg, C. , Tildon, J. T. (1999). Gastrointestinal abnormalities in children with autistic disorder.. Journal of Pediatrics, 135, 559– 563 First citation in articleCrossref MedlineGoogle Scholar

  • Irons, M. , Elias, E. R. , Abuelo, D. (1993). Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet, 341, 1414– First citation in articleGoogle Scholar

  • Jaeken, J. , van den Berghe, G. (1988). An infantile autistic syndrome characterised by the presence of succinylpurines in body fluids. Lancet, 335, 1058– 1061 First citation in articleGoogle Scholar

  • Jaeken, J. , Wadman, S. K. , Duran, M. , van Sprang, F. J. , Beemer, F. A. , Holl, R. A. , Theunissen, P. M. , de Cock, P. , van den Bergh, F. , Vincent, M. F. (1988). Adenylosuccinase deficiency: an inborn error of purine nucleotide synthesis. . European Journal of Pediatrics, 148, 126– 131 First citation in articleGoogle Scholar

  • Jaeken, J. , Jacobs, C. , Wevers, R. (2000). Disorders of neurotransmission. In: J. Fernandes, J.-M. Saudubray & G. van den Berghe (Eds.), Inborn metabolic diseases (third edition; 300– 311 Berlin Heidelberg New York: Springer-Verlag. First citation in articleGoogle Scholar

  • Jira, P. , Wevers, R. , de Jong, J. , Rubio-Gozalbo, E. , Smeitink, J (1997). New treatment strategy for Smith-Lemli-Opitz syndrome. Lancet, 349, 1222– First citation in articleCrossref MedlineGoogle Scholar

  • Jira, P. E. , Wevers, R. A. , de Jong, J. , Rubio-Gozalbo, E. , Janssen-Zijlstra, F. S. , van Heyst, A. F. , Sengers, R. C. , Smeitink, J. A. (2000). Simvastatin. A new approach for Smith-Lemli-Opitz syndrome. Journal of Lipid Research, 41, 1339– 1346 First citation in articleCrossref MedlineGoogle Scholar

  • Kelly, R. I. , Hennekam, R. C. H. (2001). Smith-Lemli-Opitz syndrome. In: C. R. Scriver, A. L. Beaudet, W. S. Sly & D. Valle (Eds.), The metabolic and molecular basis of inherited disease 8th edition 6183– 6201 New York: McGraw Hill. First citation in articleGoogle Scholar

  • Kleijnen, J. , Knipschild, P. (1991). Niacin and vitamin B6 in mental functioning: a review of controlled trials. Biological Psychiatry, 29, 931– 941 First citation in articleCrossref MedlineGoogle Scholar

  • Knivsberg, A. , Wiig, K. , Lind, G. , Nogland, M. , Reichelt, K. L. (1990). Dietary intervention in autistic syndromes. Developmental Brain Dysfunction, 3, 315– 327 First citation in articleGoogle Scholar

  • Leuzzi, V. (2002). Inborn errors of creatine metabolism and epilepsy: clinical features, diagnosis, and treatment. Journal of Child Neurology, 17 Supplement 3, 89– 97 First citation in articleGoogle Scholar

  • Levy, S. E. , Souders, M. C. , Wray, J. , Jawad, A. F. , Gallagher, P. R. , Coplan, J. , Belchic, J. K. , Gerdes, M. , Mitchell, R. , Mulberg, A. E. (2003). Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. Archives of Disease in Childhood, 88, 731– 736 First citation in articleCrossref MedlineGoogle Scholar

  • Lingam, R. , Simmons, A. , Andrews, N. , Miller, E. , Stowe, J. , Taylor, B. (2003). Prevalence of autism and parentally reported triggers in a north east London population. Archives of Disease in Childhood, 88, 666– 670 First citation in articleCrossref MedlineGoogle Scholar

  • Madsen, K. M. , Hvid, A. , Vestergaard, M. , Schendel, D. , Wohlfahrt, J. , Thorsen, P. , Osen, J. , Melbye, M. (2002). A population-based study of measles, mumps, and rubella vaccination and autism. The New England Journal of Medicine, 347, 1477– 1482 First citation in articleCrossref MedlineGoogle Scholar

  • Mercimek-Mahmutoglu, S. , Stöckler-Ipsiroglu, S. (2004). Clinical and biochemical characteristics of creatine deficiency syndromes. In: E. Klepper (Ed.), Brain metabolism revisited - concepts and treatments 58– 68 Heilbronn: SPS-Verlagsgesellschaft First citation in articleGoogle Scholar

  • Nowell, M. A. , Hackney, D. B. , Muraki, A. S. , Coleman, M. (1990). Varied MR appearance of autism: fifty-three pediatric patients having the full autistic syndrome. Magnetic Resonance Imaging, 8, 811– 816 First citation in articleCrossref MedlineGoogle Scholar

  • Ornitz, E. , Guthrie, D. , Farley, A. J. (1977). The early development of autistic children. Journal of Autism and Childhood Schizzophrenia, 7, 207– 229 First citation in articleCrossref MedlineGoogle Scholar

  • Page, T. (2000). Metabolic approaches to the treatment of autism spectrum disorders. Journal of Autism and Developmental Disorders, 30, 463– 469 First citation in articleCrossref MedlineGoogle Scholar

  • Page, T. , Yu, A. , Fontanesi, J. , Nyhan, W. L. (1997). Developmental disorder associated with increased cellular nucleotidase activity. Proceedings of the National Academy of Sciences of the USA, 94, 1601– 1606 First citation in articleCrossrefGoogle Scholar

  • Pearl, P. L. , Nowotny, E. J. , Acosta, M. T. , Jacobs, C. , Gibson, K. M. (2003). Succinic semialdehyde dehydrogenase deficiency in children and adults. Annals of Neurology, 54 Supplement 6, 73– 80 First citation in articleCrossrefGoogle Scholar

  • Plioplys, A. V. (1998). Intravenous immunoglobulin treatment of children with autism. Journal of Child Neurology, (13). 79– 82 First citation in articleCrossref MedlineGoogle Scholar

  • Race, V. , Marie, S. , Vincent, M.-F. , van den Berghe, G. (2000). Clinical, biochemical, and molecular genetic correlations in adenylosuccinate lyase deficiency. Human Molecular Genetics, 9, 2159– 2165 First citation in articleCrossref MedlineGoogle Scholar

  • Reichelt, K. L. , Knivsberg, A. , Lind, G. , Nodland, M. (1991). Probable etiology and possible treatment of childhood autism. Brain Dysfunction, 4, 323– 334 First citation in articleGoogle Scholar

  • Reichelt, K. L. , Knivsberg, A. , Nodland, M. , Lind, G. (1994). Nature and consequences of hyperpeptiduria and bovine casomorphins found in autistic syndromes. Developmental Brain Dysfunction, 7, 71– 85 First citation in articleGoogle Scholar

  • Renzoni, E. , Beltrami, V. , Sestini, P. , Pompella, A. , Menchetti, G. , Zapella, M. (1995). Brief report: allergological evaluation of children with autism. Journal of Autism and Developmental Disorders, 25, 327– 333 First citation in articleCrossref MedlineGoogle Scholar

  • Salerno, C. , D’Euphemia, P. , Finocchiaro, R. , Celli, M. , Spalice, A. , Ianetti, P. , Crifo, C. , Giardini, O. (1999). Effect of D-ribose on purine synthesis and neurological symptoms in a patient with adenylsuccinase deficiency. Biochimica et Biophysica Acta, 1453, 135– 140 First citation in articleGoogle Scholar

  • Salerno, C. , Crifo, C. , Curatolo, P. , Ciardo, F. (2000). Effect of uridine administration to a patient with adenylosuccinate lyase deficiency. Advances in Experimental Medicine and Biology, 486, 75– 78 First citation in articleCrossref MedlineGoogle Scholar

  • Sandler, A. D. , Sutton, K. A. , DeWeese, L. , Girardi, M. A. , Sheppard, V. , Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine, 341, 1801– 1806 First citation in articleCrossref MedlineGoogle Scholar

  • Sivendran, S. , Patterson, D. , Spiegel, E. , McGown, I. , Cowley, D. , Colman, R. F. (2004). Two novel mutant human adenylosuccinate lyases (ASLs) associated with autism and characterization of the equivalent mutant bacillus subtilis ASL. . The Journal of Biological Chemistry, 51, 53789– 53797 First citation in articleCrossrefGoogle Scholar

  • Shaw, W. , Kassen, E. , Chavez, E. (1995). Increased urinary excretions of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clinical Chemistry, 41, 1094– 1104 First citation in articleCrossref MedlineGoogle Scholar

  • Smeeth, L. , Hall, A. J. , Rodrigues, L. C. , Huang, X. , Smith, P. G. , Fombonne, E. (2003). Measles, mumps, and rubella (MMR) vaccine and autism: ecological studies cannot answer main question. British Medical Journal, 323, 163– First citation in articleCrossrefGoogle Scholar

  • Smith, I. , Lee, P. (2000). The hyperphenylalaninaemias. In: J. Fernandes, J.-M. Saudubray, G. & van den Berghe (Eds.), Inborn metabolic diseases (third edition 170– 184 Berlin Heidelberg New York: Springer-Verlag First citation in articleGoogle Scholar

  • Sponheim, E. , Oftedal, G. , Helverschou, S. B. (2002). Multiple doses of secretin in the treatment of autism: a controlled study. Acta Pediatrica, 91, 540– 545 First citation in articleCrossref MedlineGoogle Scholar

  • Starck, L. , Lövgren-Sandblom, A. , Björkhem, I. (2002). Simvastatin treatment in the SLO syndrome: a safe approach? . American Journal of Medical Genetics, 113, 183– 189 First citation in articleCrossref MedlineGoogle Scholar

  • Stöckler, S. , Holzbach, U. , Hanefeld, F. , Marquardt, I. , Helms, G. , Requart, M. , Hanicke, W. , Frahm, J. (1994). Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatric Research, 36, 409– 413 First citation in articleCrossref MedlineGoogle Scholar

  • Stromberger, C. , Bodamer, O. A. , Stöckler-Ipsiroglu, S. (2003). Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. Journal of Inherited Metabolic Disorders, 26, 299– 308 First citation in articleCrossref MedlineGoogle Scholar

  • Sturmey, P. (2005). Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomised controlled trials. Research in Developmental Disabilities, 26, 87– 97 First citation in articleCrossref MedlineGoogle Scholar

  • Szatmari, P (2003). The causes of autism spectrum disorders. British Medical Journal, 326, 173– 174 First citation in articleCrossref MedlineGoogle Scholar

  • Taylor, B. , Miller, E. , Farrington, C. P. , Petropoulos, M. C. , Favot-Mayaud, J. , Waight, P. A. (1999). Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet, 353, 2026– 2029 First citation in articleCrossref MedlineGoogle Scholar

  • Tierney, E. , Nwokoro, N. A. , Kelley, R. I. (2000). Behavioral phenotype of RSH/Smith-Lemli-Opitz syndrome. MRDD Research Reviews, 6, 131– 134 First citation in articleGoogle Scholar

  • Tierney, E. , Nwokoro, N. A. , Porter, F. D. , Freund, L. S. , Ghuman, J. K. , Kelley, R. I. (2001). Behavioral phenotype in the RSH/Smith-Lemli-Opitz syndrome. American Journal of Medical Genetics, 98, 191– 200 First citation in articleCrossref MedlineGoogle Scholar

  • Ulvi, H. , Müngen, B. , Yakinci, C. , Yoldas, T. (2002). Pyridoxine-dependent seizures: long-term follow-up of two cases with clinical and MRI findings, and pyridoxine treatment. Journal of Tropical Pediatrics, 48, 303– 306 First citation in articleCrossref MedlineGoogle Scholar

  • Van den Berghe, G. , Vincent, M. F. , Jaeken, J. (1997). Inborn errors of the purine nucleotide cycle: adenylosuccinase deficiency. Journal of inherited Metabolic Diseases, 20, 193– 202 First citation in articleCrossref MedlineGoogle Scholar

  • Van den Berghe, G. , Vincent, M.-F. , Marie, S. (2000). Disorders of purine and pyrimidine metabolism. . In: J. Fernandes, J.-M. Saudubray, G. & van den Berghe (Eds.), Inborn metabolic diseases third edition 353– 368 Berlin Heidelberg New York: Springer-Verlag First citation in articleCrossrefGoogle Scholar

  • Van der Knaap, M. S. , Verhoeven, N. M. , Maaswinkel-Mooij, P. , Pouwels, P. J. , Onkenhout, W. , Peeters, E. A. , Stöckler-Ipsiroglu, S. , Jakobs, C. (2000). Mental retardation and behavioral problems as presenting signs of a creatine synthesis defect. Annals of Neurology, 47, 540– 543 First citation in articleGoogle Scholar

  • Van Gennip, A. H. , Abeling, N. G. G. M. , Vreken, P. , van Kuilenburg, A. B. (1997). Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. Journal of Inherited Metabolic Disorders, 20, 203– 213 First citation in articleCrossref MedlineGoogle Scholar

  • Van Gennip, A. H. , van Kuilenburg, A. B. (2000). Defects of pyrimidine degradation: clinical, molecular and diagnostic aspects. Advances in Experimental Medicine and Biology, 486, 233– 241 First citation in articleCrossref MedlineGoogle Scholar

  • Volkmar, F. R. , Pauls, D. (2003). Autism. Lancet, 362, 1133– 1141 First citation in articleCrossref MedlineGoogle Scholar

  • Wakefield, A. J. , Murch, S. , Anthony, A. , Linnell, J. , Casson, D. M. , Malik, M. , Berelowitz, M. , Dhillon, A. P. , Thomson, M. A. , Harvey, P. , Valentie, A. , Davies, S. E. , Walker-Smith, J. A. (1998). Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet, 351, 637– 641 First citation in articleCrossref MedlineGoogle Scholar